• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Indivior PLC

    10/4/24 6:01:38 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    SC 13D 1 ef20036708_sc13d.htm SC 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     


    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.)*



    INDIVIOR PLC
    (Name of Issuer)

    Ordinary Shares, $0.50 nominal value per share
    (Title of Class of Securities)

    G4766E116
    (CUSIP Number)

    Richard Ting
    General Counsel & Managing Director
    Oaktree Capital Group Holdings GP, LLC
    333 South Grand Avenue, 28th Floor
    Los Angeles, California 90071

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
    October 2, 2024
    (Date of Event Which Requires Filing of this Statement)
     


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box. ☒
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including

    all exhibits. See §240 13d-7 for other parties to whom copies are to be sent.

    1       The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     

    *
    information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes’).
     


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Value Opportunities Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    5,438,996
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    5,438,996
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,438,996
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.1%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     

    1)
    Calculated based on 133,895,931 Ordinary Shares outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on July 16, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree London Liquid Value Opportunities Fund (VOF), L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,351,370
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,351,370
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,351,370
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.8%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Phoenix Investment Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    268,780
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    268,780
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    268,780
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.2%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Management, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☒

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,316,274
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,316,274
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,316,274
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Fund GP I, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    8,059,146
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    8,059,146
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    8,059,146
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Holdings, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,375,420
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,375,420
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,375,420
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Group Holdings GP, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,375,420
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,375,420
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,375,420
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Brookfield Asset Management ULC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Columbia, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,375,420
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,375,420
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,375,420
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    Item 1.
    Security and Issuer
     
    This Schedule 13D (this “Schedule 13D”) relates to the Ordinary Shares, $0.50 nominal value per share (the “Ordinary Shares”), of Indivior PLC, a public limited company organized under the laws of England and Wales (the “Issuer”), with its principal executive offices located at 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235.
     
    Item 2.
    Identity and Background
     
    (a)-(c), (f)
    This Schedule 13D is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):
     
     
    (i)
    Oaktree Value Opportunities Fund, L.P (“OVO Fund”);
     
    (ii)
    Oaktree London Liquid Value Opportunities Fund (VOF), L.P. (“VOF”);
     
    (iii)
    Oaktree Phoenix Investment Fund, L.P. (“OPI Fund”);
     
    (iv)
    Oaktree Capital Management, L.P. (“OC Management”);

    (v)
    Oaktree Fund GP I, L.P. (“Oaktree GP I”), as indirect general partner of OVO Fund, VOF and OPI Fund;

    (vi)
    Oaktree Capital Holdings, LLC (“OC Holdings”), as indirect general partner of OVO Fund, VOF, OPI Fund and Oaktree GP I;

    (vii)
    Oaktree Capital Group Holdings GP, LLC (“OC Group Holdings” and, together with each of the foregoing, the “Oaktree Entities”), in its capacity as the indirect owner of Class B Units of OC Holdings;
     
    (viii)
    Brookfield Asset Management ULC (“Brookfield”).
     
    The principal business of Brookfield is operations as a leading global alternative asset manager. The principal business address of Brookfield is Brookfield Place, Suite 100, 181 Bay Street, P.O. Box 762, Toronto, Ontario, Canada M5J 2T3.
     
    The principal business of the Oaktree Entities is investment management, specializing in alternative investments.  The principal business address of the Oaktree Entities is 333 S. Grand Avenue, 28th Floor, Los Angeles, CA 90071.
    (d)-(e)
    With respect to each of the Reporting Persons, (i) during the last five years, the Reporting Person has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors); and (ii) except as set forth below, during the last five years, the Reporting Person has not been party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     
    On September 25, 2024, the SEC accepted an offer by OC Management to resolve an investigation involving Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rules 13d-2 and 16a-3 thereunder, which require certain investors, like the Reporting Persons, that beneficially own the registered equity securities of a public company to file reports with the SEC of their beneficial ownership in the equity of the company, including changes in their beneficial ownership, within specified timeframes.  OC Management cooperated immediately and fully with the SEC’s investigation, and, without admitting or denying the SEC’s findings, in a settled proceeding agreed to cease and desist from committing or causing any violations and any future violations of Sections 13(d) and 16(a) of the Exchange Act and Rules 13d-2 and 16a-3 thereunder and to pay a $375,000 penalty.
     

    Item 3.
    Source and Amount of Funds or Other Consideration
     
    The securities reported herein and described in more detail in Item 4 were purchased with working capital in open market transactions.
     
    Item 4.
    Purpose of Transaction.
     
    The Reporting Persons acquired the Ordinary Shares for investment purposes. The Reporting Persons intend to review their investment in the Issuer on an ongoing basis and, in the course of their review, may take actions (including through their affiliates) with respect to their investment or the Issuer, including communicating with the board of directors of the Issuer (the “Board”), members of management or other security-holders of the Issuer, or other third parties from time to time, and taking steps to implement a course of action, including, without limitation, engaging advisors, including legal, financial, regulatory, technical and/or industry advisors.

    The Reporting Persons intend to engage in discussions with the Board and management of the Issuer regarding opportunities to enhance stockholder value, including through changes to the Issuer’s capital allocation and capital structure, and exploration of strategic alternatives, including, without limitation, a potential sale of the Issuer.

    The Reporting Persons also may engage in discussions and take other actions relating to various alternative courses of action, including, without limitation, those related to potential business combinations or dispositions involving the Issuer or any of its subsidiaries, or their businesses or assets, including transactions in which the Reporting Persons may seek to participate and potentially engage in; changes in the present business, operations, strategy, future plans or prospects of the Issuer, financial or governance matters; changes to the Board (including board composition) or management of the Issuer; changes to the capitalization, ownership structure, dividend policy, business or corporate structure or governance documents of the Issuer; de-listing or de-registration of the Issuer’s securities, or any action similar to those enumerated above.

    The Reporting Persons or their affiliates may seek to acquire some or all securities of the Issuer, including Ordinary Shares and/or other equity, debt, notes or other financial instruments related to the Issuer or the Ordinary Shares (which may include rights or securities exercisable or convertible into securities of the Issuer), and/or sell or otherwise dispose of some or all of such Issuer securities or financial instruments (which may include distributing some or all of such securities to such Reporting Person’s respective partners or beneficiaries, as applicable) from time to time, in each case, in open market or private transactions, block sales or otherwise. Any transaction that any of the Reporting Persons or their affiliates may pursue will depend on a variety of factors, including, without limitation, the price and availability of the Issuer’s securities or other financial instruments, the Reporting Persons’ or such affiliates’ trading and investment strategies, subsequent developments affecting the Issuer, the Issuer’s business and the Issuer’s prospects, other investment and business opportunities available to such Reporting Persons and their affiliates, general industry and economic conditions, the securities markets in general, tax considerations and other factors deemed relevant by such Reporting Persons and such affiliates.
     
    None of the Reporting Persons, and to the best of their knowledge, none of the Covered Persons, has any current plan or proposal which relate to or would result in any of the matters described in Items 4(a) - (j) of Schedule 13D, except as described in this Schedule 13D or as would occur upon, in connection with completion of, or following, any of the actions described in this Schedule 13D
     

    Item 5.
    Interest in Securities of the Issuer.
     
    (a), (b) and (c)
    The information set forth in rows (7) through (11) of the cover pages of this Schedule 13D is incorporated by reference into this Item 5.
     
    The Reporting Persons hold an aggregate of 9,375,420 shares of Common Stock, representing 7.0% of the Common Stock outstanding as of the date hereof. All such ownership percentages of the securities reported herein are calculated assuming 133,895,931 Ordinary Shares outstanding as reported by the Issuer in its Form 6-K filed with the SEC on July 16, 2024.
     
    In this regard, OVO Fund is the direct holder of 5,438,996 Ordinary Shares. VOF Fund is the direct holder of 2,351,370 Ordinary Shares. OPI Fund is the direct holder of 268,780 Ordinary Shares. OC Management is the investment manager to Boston Patriot Arlington St LLC, an SMA account which directly holds 1,316,274 Ordinary Shares. Oaktree GP I is the indirect general partner of OVO Fund, VOF, and OPI Fund, and as such may be deemed to beneficially own an aggregate of 8,059,146 Ordinary Shares. OC Holdings is the indirect general partner of OVO Fund, VOF, OPI Fund, and Oaktree GP I, and as such may be deemed to beneficially own an aggregate of 9,375,420 Ordinary Shares. OC Group Holdings is the indirect owner of the Class B Units of OC Holdings, and as such may be deemed to beneficially own an aggregate of 9,375,420 Ordinary Shares. Brookfield is the indirect owner of the Class A1 Units OC Holdings, and as such may be deemed to beneficially own an aggregate of 9,375,420 Ordinary Shares. Each of the Reporting Persons disclaims beneficial ownership of the reported securities and the filing of this Statement shall not be construed as an admission of such beneficial ownership for the purposes of Section 13(d) or 13(g) of the Exchange Act.
     
    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that it is the beneficial owner of any of the Common Stock referred to herein for the purposes of Section 13(d) of the Act, or for any other purpose.
     
    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
     
    Not Applicable.
     
    Item 7.
    Material to be Filed as Exhibits
     
    Exhibit 24.1
    Joint Filing Agreement, dated as of October 3, 2024, by and among the reporting persons.


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: October 3, 2024
     
     
    OAKTREE VALUE OPPORTUNITIES FUND, L.P.
     

     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE LONDON LIQUID VALUE OPPORTUNITIES FUND (VOF), L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE PHOENIX INVESTMENT FUND, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE CAPITAL MANAGEMENT, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE FUND GP I, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE CAPITAL HOLDINGS, LLC
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory


     
    OAKTREE CAPITAL GROUP HOLDINGS GP, LLC
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    BROOKFIELD ASSET MANAGEMENT ULC
         
     
    By:
    /s/ Kathy Sarpash
     
    Name:
    Kathy Sarpash
     
    Title:
    Managing Director, Legal & Regulatory



    Get the next $INDV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    8/6/2025$27.00Buy
    H.C. Wainwright
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    SEC Filings

    View All

    Indivior PLC filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INDIVIOR PLC (0001625297) (Filer)

    11/20/25 4:07:07 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior PLC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INDIVIOR PLC (0001625297) (Filer)

    11/14/25 9:05:14 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Indivior PLC

    SCHEDULE 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/13/25 4:27:43 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Indivior Concludes Legacy U.S. Department of Justice Matter

    RICHMOND, Va., Nov. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with the DOJ will be terminated. The payment was funded with Indivior's cash on hand. "We are pleased to reach this important milestone that concludes the legacy DOJ matter," said Joe Ciaffoni, Chief Executive Officer. "It removes a significant liability and simpli

    11/20/25 4:01:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

    RICHMOND, Va., Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th Annual Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Tuesday, December 2nd. Joe Ciaffoni and Ryan Preblick will also participate in a fireside discussion on Tuesday, December 2nd at 3:30 p.m. U.S. EST. Interested investors should contact their Piper Sandler representative to schedul

    11/19/25 9:21:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Indivior with a new price target

    H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00

    8/6/25 8:01:45 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Indivior with a new price target

    Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

    7/22/25 7:52:44 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Indivior with a new price target

    Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

    1/28/25 7:14:13 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Financials

    Live finance-specific insights

    View All

    Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

    Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

    10/30/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

    RICHMOND, Va., Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begi

    10/16/25 4:04:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

    Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-YearIndivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call Scheduled for Today at 8:00 A.M. EDTRICHMOND, Va., July 31, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the second quarter ended June 30, 2025, and provided a business update. "SUBLOCADE® net revenue and pricing stability in SUBOXONE® Film in the U.S. drove solid results in the second quarter, leading us to raise our 2025 financial guidan

    7/31/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

    RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

    7/8/25 8:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Appoints Tony Kingsley to the Board of Directors

    RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

    6/24/25 4:12:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

    11/7/24 8:23:16 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care